Want to see ATHE full AI Analyst Report?
ATHE Stock Chart & Stats
$3.55
-$0.16(-4.23%)
At close: 4:00 PM EST
$3.55
-$0.16(-4.23%)
Day’s Range― - ―
52-Week Range$2.66 - $7.00
Previous CloseN/A
Volume131.33K
Average Volume (3M)13.05K
Market Cap
$97.98M
Enterprise Value$78.21M
Total Cash (Recent Filing)$49.15M
Total Debt (Recent Filing)$98.35K
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding18,126,081
10 Day Avg. Volume16,981
30 Day Avg. Volume13,055
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.56
Price to Sales (P/S)12.18
P/FCF Ratio-5.79
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue20.40
Enterprise Value/Gross Profit21.07
Enterprise Value/Ebitda-3.94
Forecast
1Y Price Target
$12.67Price Target Upside256.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.56
Revenue Forecast (FY)$4.21M
Bulls Say, Bears Say
Bulls Say
Regulatory De-risking — FDA Alignment For Phase 3FDA agreement on trial size, dose, endpoint and statistical approach materially reduces regulatory uncertainty for ATH434. This alignment shortens path to registrational data, clarifies development milestones, and supports credible planning for a pivotal readout and potential U.S. approval over the coming 2–3 years.
High Gross MarginsConsistently >90% gross margins indicate a scalable small‑molecule therapeutic model with low incremental cost of goods. If ATH434 reaches commercialization, high gross margins would support durable operating leverage, allowing revenues to translate efficiently into improved operating profitability over time.
Validated Biomarkers And Supportive Phase 2 DataObjective MRI biomarker validation and Phase 2 signals (clinical slowing, imaging and CSF biomarker changes) strengthen trial endpoint credibility and target biology rationale. Robust biomarkers improve trial sensitivity, reduce trial risk, and support efficient Phase 3 design and potential differentiation in a niche CNS indication.
Bears Say
Negative Operating And Free Cash FlowSustained negative operating and free cash flows erode liquidity and force reliance on external financing or dilutive capital raises to fund development. Over a multi‑quarter horizon this constrains R&D capacity, increases financing risk, and can delay pivotal programs absent committed funding.
Lack Of Profitability / Negative ROENegative ROE reflects persistent losses and indicates current capital is not yielding returns. Until a late‑stage asset reaches approval or commercialization, shareholders face an extended timeline to see positive returns, pressuring capital allocation and elevating governance scrutiny on financing strategy.
Reliance On Capital Markets / Potential DilutionFrequent filings updating registration statements, notifications on unquoted securities and corporate presentation incorporations signal active capital‑markets management and preserved financing flexibility. Given negative cash flow, this suggests continued dependence on equity issuance, raising dilution risk for existing holders over the medium term.
Alterity Therapeutics News
ATHE FAQ
What was Alterity Therapeutics Ltd’s price range in the past 12 months?
Alterity Therapeutics Ltd lowest stock price was $2.66 and its highest was $7.00 in the past 12 months.
What is Alterity Therapeutics Ltd’s market cap?
Alterity Therapeutics Ltd’s market cap is $97.98M.
When is Alterity Therapeutics Ltd’s upcoming earnings report date?
Alterity Therapeutics Ltd’s upcoming earnings report date is Mar 04, 2027 which is in 242 days.
How were Alterity Therapeutics Ltd’s earnings last quarter?
Alterity Therapeutics Ltd released its earnings results on Feb 25, 2026. The company reported -$0.415 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.165.
Is Alterity Therapeutics Ltd overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd’s price is currently Undervalued.
Does Alterity Therapeutics Ltd pay dividends?
Alterity Therapeutics Ltd does not currently pay dividends.
What is Alterity Therapeutics Ltd’s EPS estimate?
Alterity Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alterity Therapeutics Ltd have?
Alterity Therapeutics Ltd has 18,126,081 shares outstanding.
What happened to Alterity Therapeutics Ltd’s price movement after its last earnings report?
Alterity Therapeutics Ltd reported an EPS of -$0.415 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went up 2.945%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd?
Currently, no hedge funds are holding shares in ATHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.67 (256.81% Upside)
$12.67 (256.81% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
43.18%
12-Months-Change
Fundamentals
Return on Equity
-30.19%
Trailing 12-Months
Asset Growth
481.25%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
ATHE Stock 12 Month Forecast
Average Price Target
$12.67
▲(256.81% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.94% Other Institutional Investors
99.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---